Royce & Associates’s PTC Therapeutics PTCT Stock Holding History

Royce & Associates’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$777K	Sell	9,523 -83,305	-90%	-$6.02M	0.01%	690
2026 Q1	$6.32M	Buy	92,828 +12,034	+15%	+$852K	0.06%	426
2025 Q4	$6.14M	Buy	80,794 +48,015	+146%	+$3.49M	0.06%	425
2025 Q3	$2.01M	Sell	32,779 -17,458	-35%	-$909K	0.02%	592
2025 Q2	$2.45M	Buy	+50,237	New	+$2.38M	0.03%	572
2015 Q1	–	Sell	-50,000	Closed	-$2.59M	–	1285
2014 Q4	$2.59M	Hold	50,000	–	–	0.01%	928
2014 Q3	$2.2M	Hold	50,000	–	–	0.01%	988
2014 Q2	$1.31M	Buy	+50,000	New	+$1.07M	﹤0.01%	1114

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Royce & Associates's PTCT Position: Q2 2026 in Review

Royce & Associates reduced its PTC Therapeutics (PTCT) stake by 90% in Q2 2026, selling an estimated $6.02M and leaving 9,523 shares worth $777K. The position accounts for 0.01% of the portfolio, ranked #690.

Royce & Associates first reported a position in PTCT in Q2 2014 and has held it in 8 quarters since. The position peaked at $6.32M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Royce & Associates held 9,523 shares of PTC Therapeutics worth $777K as of Q2 2026.
Royce & Associates sold 83,305 PTC Therapeutics shares in Q2 2026, an estimated $6.02M.
PTC Therapeutics made up 0.01% of Royce & Associates's portfolio in Q2 2026, its #690 holding.
Royce & Associates first reported a position in PTC Therapeutics in Q2 2014 and has held it in 8 quarters since.
Royce & Associates's PTC Therapeutics position peaked at $6.32M in Q1 2026.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.